Cancer is a challenging disease to both understand and treat, and was responsible for 17.8% of total deaths worldwide in 2020, coming closer to the 20.6% of deaths associated with cardiovascular disease. Despite global oncology spending of 167 billion US dollars in 2020, the prognosis of most cancers, especially advanced-stage diseases, remains poor because of therapy resistance. With much emphasis and many resources placed on oncological research, progress in precancer screening, anticancer treatments, and supportive care all contribute to better survival rates and quality of life for cancer patients. However, given the diversity of treatment outcomes and complexity of adverse effects, oncology research is in desperate need of reformation. As oncology has evolved to include more fields and novel concepts, Cancer Innovation has been created to bring innovation into cancer research. The technological breakthrough is the prime driving force for progress in biomedical research. Currently, oncology is a rapidly evolving research field filled with an increasing volume of biological and medical data. This is especially marked by the variety of multiomic data types, including but not limited to genomic, proteomic, metabolic, clinical phenotype, and imaging data. Given the heterogeneous nature of cancer, variations in patient baseline characteristics, and unpredictable responses to therapies, a novel technique-driven data mining approach for cancer identification may provide additional insights. The availability of medical big data and the information they may provide regarding cancer biology are the most exciting indications of movements toward precision medicine, where prevention, diagnosis, and treatment are personally tailored based on the specific molecular characteristics of an individual patient's disease. However, many challenges remain for precision medicine. Although multidimensional data of cancer are continuously accumulating, we still lack the ideal logistics and platforms to integrate and analyze these data and interpret cancer biology concepts from them. Creating a scientific community to help researchers manage large amounts of clinical and biological data, in addition to providing a platform for open discussion and learning, is one of the main goals of this journal. A combination of treatment methods, including surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy, are currently available depending on each patient's particular situation, while each treatment meets its limitation in clinical practice. Additionally, the complications and adverse effects of anticancer therapies all pose significant threats to the patient's overall survival. However, many necessary fields remain underdeveloped: new therapies and drug candidates, drug delivery systems, biomarkers for disease phenotyping, and especially the integration of other medical subspecialties with the help of nonmedical subjects. The future approach to standardized, comprehensive, and multidisciplinary cancer management is still vague. Therefore, a multidisciplinary approach is crucial to improving treatment efficiency and quality of care. In addition to oncologists and medical experts, scientists from various disciplines such as biology, pharmaceuticals, physics, chemistry, mathematics, and computer science must collaborate to develop new strategies for the diagnosis and treatment of cancer. The establishment of a successful multidisciplinary community is quite difficult and requires efficient organization of all scientific members. Scientific advancements and good communication within the multidisciplinary team will help the clinicians in the decision-making process and pave the way for a more applicable multidisciplinary management strategy. Cancer Innovation is an open access and peer-reviewed journal devoted to publishing high-quality original articles, clinical guidelines, technical reports, editorials, reviews, case reports, commentaries, news, study protocols, meta-analyses, and other publication types. This journal highlights the multidisciplinary integration in innovative oncology and aims to promote interdisciplinary oncology research and management of comorbidities across medical subspecialties. With this journal, we hope to begin a journey to find the solutions to innovative oncology problems, establish a hub for collaboration and communication across disciplines, and present a high-quality platform for deepening our understanding of oncology and developing guidelines for clinical decisions. We will present a unique combination of oncology translational research, interspecialty integration, and data sciences, bringing us one step closer to precision oncology and a better future for cancer patients. Finally, I would like to express my appreciation to the honorary chief editors for their help and encouragement with this new journal. With support and cooperation to overcome the difficulties that may arise, I am confident that we will have a brighter future for cancer prevention and treatment. We look forward to receiving your contributions!